In short
Clinical trials are investigating Xp-Dc+Tl+Klh in women with epithelial ovarian cancer. The studies are looking at whether this treatment can trigger an immune response and help during neoadjuvant or adjuvant chemotherapy. They also assess early safety and biological activity in small patient groups.
Key points
- Clinical trials of Xp-Dc+Tl+Klh are studying epithelial ovarian cancer, especially in patients receiving neoadjuvant or adjuvant chemotherapy. The main trial is a Phase 1/2 interventional study called NEODOC. It focused on whether tumor-lysate loaded XP-DC could induce or improve an immune response. The study enrolled 10 participants and was completed. The main endpoint was immunological efficacy, meaning the researchers wanted to see if the treatment could trigger a measurable immune reaction.
Trial overview
The clinical trial in the source data studied Xp-Dc+Tl+Klh in women with epithelial ovarian cancer. The study was called the NEODOC study and was designed to test whether tumor-lysate loaded XP-DC could improve the immune response in patients receiving chemotherapy.
This was an interventional study, which means the research team gave a study treatment and then measured the results. The study was completed and enrolled 10 participants.
Who was studied
The trial focused on patients with epithelial ovarian cancer, a type of ovarian cancer that starts in the cells covering the ovary. The study description shows that the target group was patients treated with neoadjuvant chemotherapy or (neo-)adjuvant chemotherapy.
Neoadjuvant chemotherapy means treatment given before the main cancer treatment, and adjuvant chemotherapy means treatment given after the main treatment to help lower the chance of cancer returning. The trial therefore looked at a fairly specific patient group rather than a broad cancer population.
Study design and phase
The study was a Phase 1/2 trial. Early-phase trials like this are usually done to look for signs of safety and early activity, before larger studies are planned.
The intervention was listed as Drug: XP-DC+TL+KLH (INTRANODAL). The source data also says the study used tumor-lysate loaded XP-DC in epithelial ovarian cancer patients undergoing chemotherapy.
What was measured
The main endpoint, also called the primary outcome, was the immune response enhanced or induced by autologous tumor lysate-loaded XP-DC in epithelial ovarian cancer patients. A primary outcome is the main result the researchers plan to measure.
The brief summary says the main objective was to show immunological efficacy of tumor-lysate loaded XP-DC in patients undergoing chemotherapy. Immunological efficacy means the treatment was being tested for its ability to create a useful immune effect in the body.
Key trial details
| Item | Information from the trial |
|---|---|
| Trial ID | NCT05773859 |
| Title | Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study |
| Status | Completed |
| Phase | Phase 1/2 |
| Condition | Ovarian cancer |
| Enrollment | 10 participants |
| Intervention | XP-DC+TL+KLH given intranodally |
| Main outcome | Immune response / immunological efficacy |
What the trial means for patients
This trial was small and early, so it was mainly designed to learn whether the treatment can trigger an immune response in a specific group of ovarian cancer patients. It did not study a broad population, but instead focused on patients already receiving chemotherapy around the time of surgery or main treatment.
Because the study was completed and only 10 people were enrolled, the data are best seen as early research evidence rather than a final answer about treatment benefit.